Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea

Clinical trial NCT05144945 · COMPLETED

Trial details

NCT number: NCT05144945
Sponsor: Sanofi Pasteur, a Sanofi Company
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Influenza (Healthy Volunteers)

Start date: 2021-12-07
Primary completion: 2022-09-01
Enrollment: 301

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.